Kalivir Immunotherapeutics, Inc.

Calculating rank

USPTO Granted Patents = 6

Trademarks = 2

Forward Citations = 0

Loading Chart...

3 inventors (with patents filed for the assignee):

Stephen Howard Thorne (6 out of 17 patents)

Mingrui Zhang (6 out of 8 patents)

Daniel J Byrd (4 out of 7 patents)

6 patents: Sort by Forward Citations

1. 12472217 - Platform Oncolytic Vector for Systemic Delivery (2025-11-18),

2. 12318419 - Platform oncolytic vector for systemic delivery (2025-06-03),

3. 12226440 - Platform oncolytic vector for systemic delivery (2025-02-18),

4. 12036257 - Platform oncolytic vector for systemic delivery (2024-07-16),

5. 12016893 - Oncolytic viruses for modified MHC expression (2024-06-25),

6. 11963990 - Oncolytic viruses for modified MHC expression (2024-04-23),

Company Overview

Kalivir Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative immunotherapies to treat various forms of cancer. Leveraging advanced technologies in molecular biology and immunology, Kalivir aims to enhance the body’s natural immune response to effectively eradicate tumors. Their proprietary platform enables the discovery and development of novel therapeutic candidates designed to activate and modulate immune pathways. Through rigorous preclinical and clinical trials, Kalivir seeks to deliver transformative treatments that improve patient outcomes while minimizing side effects associated with conventional therapies. The company's commitment to scientific excellence and patient care positions it at the forefront of the immunotherapy landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

6 Patents

#24 in

#780 in